Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction
Qi Pan,Jing Xu,Cen-Jin Wen,Yu-Yan Xiong,Zhao-Ting Gong,Yue-Jin Yang
DOI: https://doi.org/10.2147/ijn.s328723
IF: 7.033
2021-09-30
International Journal of Nanomedicine
Abstract:Qi Pan, 1 Jing Xu, 1 Cen-Jin Wen, 2 Yu-Yan Xiong, 1 Zhao-Ting Gong, 1 Yue-Jin Yang 1 1 State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China Correspondence: Yue-Jin Yang State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China Email Despite several recent advances, current therapy and prevention strategies for myocardial infarction are far from satisfactory, owing to limitations in their applicability and treatment effects. Nanoparticles (NPs) enable the targeted and stable delivery of therapeutic compounds, enhance tissue engineering processes, and regulate the behaviour of transplants such as stem cells. Thus, NPs may be more effective than other mechanisms, and may minimize potential adverse effects. This review provides evidence for the view that function-oriented systems are more practical than traditional material-based systems; it also summarizes the latest advances in NP-based strategies for the treatment and prevention of myocardial infarction. Keywords: nanoparticles, myocardial infarction, treatment, prevention The growing burden of ischemic heart disease (IHD) is a major public health issue. The most harmful type of IHD is acute myocardial infarction (MI), which leads to loss of tissue and impaired cardiac performance, accounting for two in five deaths in China. 1 Timely revascularization after MI, including percutaneous coronary intervention, thrombolytic treatment and bypass surgery, is key to improving cardiac function and preventing post-infarction pathophysiological remodeling. 2 However, these effective but invasive approaches cannot be used in all patients owing to their applicability, which is limited based on specific clinical characteristics, and the possibility of severe complications such as bleeding and reperfusion injury. 2,3 Attempts to limit infarct size and improve prognosis using pharmacotherapy (including antiplatelet and antiarrhythmic drugs and angiotensin-converting enzyme inhibitors) without reperfusion has been proven generally inefficient, due to non-targeted drug distribution and side effects, and short half-life of some drugs. 1,3,4 Consequently, many patients in which this approach is used still progress to cardiac hypertrophy and heart failure. 1 Growth and rupture of atherosclerotic plaques and the ensuing thrombosis are the major causes of acute MI. 4 Currently available interventions for atherosclerosis (AS) including statins can reduce acute MI, but the effects vary between individuals, and leave significant residual risks. 5–8 Some chemotherapies, such as docetaxel 9 and methotrexate, 10,11 also seem to have beneficial effects in AS; however, systemic administration of these drugs is limited because of their adverse effects. 12 The demand for safer and more efficient therapies and prevention strategies for MI is therefore increasing. Several optimized strategies have so far been explored, one of which is the application of nanoparticles (NPs). These nanoscale particles have been widely used in the treatment of tumors and neural diseases. 13,14 NPs enable delivery of therapeutic compounds to target sites with high spatial and temporal resolution, enhancement of tissue engineering processes and regulation of the behaviour of transplants such as stem cells. The application of NPs improves the therapeutic effects and minimizes the adverse effects of traditional or novel therapies, increasing the likelihood that they can be successfully translated to clinical settings. 15–18 However, research on NPs in this field is still in its infancy. 5,19–21 This review summarizes the latest NP-based strategies for managing acute MI, mostly published within the past 7 years, with a particular focus on effects and mechanisms rather than particle types, which have been extensively covered in other reviews (Figure 1). In addition, we offer an initial viewpoint on the value of function-based systems over those based on materials, and discuss future prospects in this field. Figure 1 Overview of nanoparticle-based strategies for the treatment and prevention of myocardial infarction. Nanoparticles are capable of -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology